Back to research feed

Alzheimer's & dementia : the journal of the Alzheimer's Association

October 1, 2026 · via Europe PMC

Spatiotemporal heterogeneity and dynamic evolution of microglial glucose metabolic reprogramming in Alzheimer's disease.

Chen Y, Li F, Zhang J, +5 more, Shi J.

ReviewOpen access

AI summary — for doctors, generated from the abstract only

This review proposes that microglial glucose metabolism in Alzheimer's disease shifts across disease stages and regions as a mix of coexisting metabolic states.

What was studied

Narrative review of microglial glucose metabolic reprogramming across stages, brain regions and plaque microenvironments, proposing a dynamic state-composition model.

Key findings

  • Early or phagocytic microglia may show enhanced glycolytic and OXPHOS programs
  • Under sustained stress, higher glucose uptake may not yield effective energy production
  • Late disease features more microglia with reduced metabolic capacity and impaired phagocytosis

Clinical relevance

May eventually inform stage- and cell-state-specific therapies, but it has no direct clinical use now.

Who should care

Neurology

Limitations

A conceptual model not yet tested; the authors say longitudinal cell tracking and microglia-specific flux measurements are needed.

A hypothesis-generating framework for microglial metabolism in AD, not clinical evidence.

This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.

Abstract

Alzheimer's disease (AD) is accompanied by persistent disturbances in brain energy metabolism, and microglial glucose metabolic reprogramming constitutes an important link among pathological protein deposition, neuroinflammation, and impaired clearance. This review examines these metabolic changes across disease stages, brain regions, and plaque-associated microenvironments and proposes a dynamic state-composition model. In this model, microglia in different metabolic states coexist, and their relative proportions and spatial distribution change as AD progresses. In early disease or during active phagocytosis, some microglia show enhanced glycolytic and oxidative phosphorylation (OXPHOS) programs. Under persistent pathological stress, increased glucose uptake may not translate into effective energy production and can coexist with inflammation and impaired lipid metabolism. In late disease, microglia with reduced metabolic capacity and impaired phagocytosis become more prevalent. However, higher expression of OXPHOS-related genes in some microglial states associated with tau pathology does not necessarily indicate improved mitochondrial respiration. These population-level patterns do not imply that individual microglia follow a fixed sequence of metabolic changes. Longitudinal cell tracking and microglia-specific metabolic flux measurements are needed to test this model and inform interventions tailored to disease stage and microglial state.

DOI

10.1002/alz.71909

PMID

42851167

Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.

Want more like this?

Browse more from the feed. A free account unlocks the full feed, saving and communities.

Back to the research feed

Create a free account · Sign in